Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.50 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28205776 | 0.98 | MAPT (0.58) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| SCHEMBL10337516 | 0.97 | MAPT (0.64) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| SCHEMBL45515 | 0.97 | MAPT (0.64) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Bromide SCHEMBL19378722 | 0.95 | MAPT (0.61) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Water SCHEMBL18694848 | 0.95 | MAPT (0.61) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Methyl Alcohol SCHEMBL27972456 | 0.93 | MAPT (0.58) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL19378455 | 0.93 | MAPT (0.58) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Sulfuric Acid SCHEMBL8748212 | 0.89 | MAPT (0.54) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Dimethylamine SCHEMBL8980382 | 0.89 | KMT2A (0.60) | MAPTTDP1CYP3A4MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.87 | GSK3B (0.42) | MAPTTDP1CYP3A4MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118549576-A | Organic nitrogen-oxygen metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof | 中国水产科学研究院长江水产研究所 | 2024-08-27 | — | — | CN | claimed |
| CN-111423432-B | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2023-01-24 | — | — | CN | claimed |
| CN-115594606-A | Asymmetric synthesis method of threo-2-hydroxy-3-acetamido-4-phenylcarbonyl butyric acid | 成都傲科新技术有限责任公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20210205260-A1 | MP53 RESCUE COMPONDS AND METHODS OF TREATING A P53 DISORDER | RUI JIN HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE (CN) | 2021-07-08 | — | — | US | claimed |
| EP-3735253-A1 | MP53 RESCUE COMPOUNDS AND METHODS OF TREATING A P53 DISORDER | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine (CN) | 2020-11-11 | — | — | EP | claimed |
| CN-111423432-A | (S) -4/5-phenyl-2- (pyrrolidine-2-yl) thiazole TRPV1 antagonist and preparation and application thereof | 河南大学 | 2020-07-17 | — | — | CN | claimed |
| CN-106636239-B | Preparation method of chloramphenicol | 苏州引航生物科技有限公司 | 2019-12-31 | — | — | CN | claimed |
| WO-2019134650-A1 | MP53 RESCUE COMPOUNDS AND METHODS OF TREATING A P53 DISORDER | RUI JIN HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2019-07-11 | — | — | WO | claimed |
| US-20160193214-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-07 | — | — | US | claimed |
| WO-2015021456-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-12 | — | — | WO | claimed |
| CN-102381991-A | Method for synthesizing DL-Octopamine hydrochloride | HANGZHOU FST PHARMACEUTICAL CO LTD | 2012-03-21 | — | — | CN | claimed |
| CN-101798271-A | Method for preparing (+/-)-norepinephrine | HANGZHOU APAC PHARMACEUTICAL TECHNOLOGY CO LTD | 2010-08-11 | — | — | CN | claimed |
| EP-0587533-B1 | Process for the preparation of alpha-aminoketone salts | CIBA GEIGY AG (CH) | 1997-03-12 | — | — | EP | claimed |
| US-5322964-A | Process for the preparation of alpha-aminoketone salts | CIBA-GEIGY CORPORATION (US) | 1994-06-21 | — | — | US | claimed |
| EP-0587533-A2 | Process for the preparation of alpha-aminoketone salts | CIBA-GEIGY AG (CH) | 1994-03-16 | — | — | EP | claimed |
| JP-60001173-A | — | — | None | — | — | JP | disclosed |
| JP-7309843-A | — | — | None | — | — | JP | disclosed |
| US-4123529-A | TREATMENT OF ASTHMA | LILLY INDUSTRIES LIMITED (GB) | 1978-10-31 | — | — | US | disclosed |
| US-4049650-A | 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205260-A1 | MP53 RESCUE COMPONDS AND METHODS OF TREATING A P53 DISORDER | TP53, TP53BP1, RAD50 | HDAC1 1844/4885HDAC2 2403/4885PARP1 523/4885 |
| US-20160193214-A1 | SMALL MOLECULES TO ENHANCE P53 ACTIVITY | TP53, TP53BP1, MDM2 | HDAC1 2257/4885HDAC2 3578/4885PARP1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.